A simple, elegant and obvious solution to the conundrum that is DVT.
Why has there been so little success in the aggressive treatment of DVT?
For 50 years, the standard of care for the treatment of Deep Venous Thrombosis, or DVT, has been anticoagulation. This strategy does very little to treat the acute symptoms of DVT: pain, swelling, and the resultant difficulty in walking. In the past 15 years, catheter directed therapy, using either pharmacologic thrombolysis, where clot-dissolving medication is directly infused into blood clots, or mechanical thrombectomy, where devices are used to extract or pulverize the clot, have entered the scene, with variable results.
While catheter directed thrombolysis had clearly demonstrated successes, such success comes at a price: the risk of the medication used, typically Tissue Plasminogen Activator, or TPA, makes its use in many cases unjustifiable. Patients subjected to this treatment may develop life-threatening bleeding in the brain or gut due its systemic effects. Patients treated in this fashion also required very close monitoring, usually in an ICU environment, often upwards of 2 days.
These drawbacks have led many to consider mechanical thrombectomy as an alternative. That is, directly removing the clot by means of some combination of clot disruption and clot extraction. The problem is, all such strategies thus far have only met with marginal success. The common theme in the relative failure of this strategy is the inability of the available systems to properly control the byproducts of the clot fragmentation upon which all the strategies depend. Newer devices tout advantages, but merely trade one problem for another: using some powerful means for suction of clot depends on there being flowing blood to wash the fragmented clot along, a veritable bloodletting which makes the process unsustainable.
The founders of EndoVention, an interventional radiologist/bioengineer and a former molecular biologist with extensive medical device experience, have developed a simple yet revolutionary technology which solves these problems in one bold stroke. It is the type of solution, when seen by physicians who treat DVT, that makes them wonder aloud how such a technology hadn’t been developed up to this point. And when you see it, you will ask the same question.
The answer is that, in spite of its seeming simplicity, actually executing such a technology requires years of development and refinement. The relentlessness of the founders and their engineering team, knowing full well the revolutionary value such a technology brings to the world, overcame all of the technical challenges in arriving at the flagship device, the Mega-Mouth™ EMC catheter. This disruptive technology not only potentially represents a paradigm shift in DVT treatment, it also provides the platform upon which existing technologies, limited in the ways described above, may be used to better advantage.